Are AI Rings False Demand? Oura's IPO Plan and Accuracy Lawsuit

AI rings occupy a peculiar position in the consumer market. They do function in that they can measure heart rate, blood oxygen, and sleep. However, they fall short of fitness trackers in terms of measurable metrics, and neither accuracy nor comfort is sufficient. According to a report by Guanwang Caijing of Huxiu, this gap is being widened by enthusiasm in the capital markets.

In early September 2026, Finland’s Oura was reported to be planning a new listing in the United States. It is said to be seeking to raise $3 billion at a valuation of over $50 billion. In contrast, Happy Health, which has taken a medical-focused path, has closed its Series A, and its flagship Happy Ring has obtained two FDA 510(k) clearances. The contrast between capital market expectations and actual user experience has become stark.

Oura is aiming for a valuation of over $50 billion in its U.S. IPO, yet its AI ring products fall far short of standards in accuracy and comfort, creating a stark contrast between user experience and capital market euphoria, with the market still at the “proof-of-concept” stage.

Oura’s IPO Plan and Financial Performance

Oura is the world’s leading company in the smart ring sector. According to its prospectus, revenue in 2024 was about $500 million. In 2025 it doubled to $1 billion, and it is projected to reach $1.5 billion to $2 billion in 2026. In the nine months through June 2026, revenue was $1.2 billion, up 72% year-on-year.

Paid subscribers surged from 1.3 million in 2024 to 5 million. The 12-month retention rate reached 85%, and 3.6 million units were sold in the past year. New CEO Tom Hale has redefined Oura less as a device manufacturer and more as a data and AI company. He has emphasized creating value not through the device alone but through analysis and advice.

Revenue Structure Built on Hardware and

Monthly Subscriptions

The flagship Ring 4 is sold for $349 to $499. A $5.99 per month subscription is required to obtain full sleep analysis and AI health advice. By revenue mix, devices account for about 80% and subscriptions for about 20%. It is a typical razor-and-blade business model.

This structure is supported by high retention. The longer members stay, the more cumulative per-user payments accumulate. Conversely, if the reliability of measurements wavers, the justification for the subscription also wavers. Device accuracy is the very foundation of the revenue model.

Harsh Criticism of Comfort and

Measurement Accuracy

The most widely known product among consumers is Samsung’s Galaxy Ring. The domestic Chinese version is priced at 2,999 yuan and the body is made of titanium. It weighs 2.3 to 3 grams and is said to feel almost weightless according to specifications. However, actual users have voiced complaints such as feeling deceived and that it was a waste of money.

In terms of functionality, some describe it as a miniaturized fitness tracker. Heart rate, blood oxygen, sleep, and body temperature are already covered by wristwatch and strap-type devices. Wrist-worn devices have a larger detection area and fit more tightly, so readings tend to be more stable. Ring-type devices are constrained by volume and must miniaturize the sensor, putting them at a disadvantage in signal acquisition.

Domestic followers were once active. Dreame released its first AI smart ring in November 2025 and claimed orders exceeded 100 million yuan in five months. In March 2026, it unveiled Glow, touting fingertip AI ECG monitoring, and appeared on a Spring Festival program. Huami launched the Amazfit Helio Ring in early 2024, and Yuwell and RingConn also entered the market.

Huawei entered on a trial basis through its Smart Selection ecosystem. Xiaomi, Honor, and OPPO were also reported to be in development. However, the excitement cooled quickly. Apart from Dreame’s sales promotion, no product has spread by word of mouth. Some manufacturers are said to have shelved plans before launch.

Class-Action Lawsuit Over Sleep Accuracy

Expands in the U.S.

More serious than comfort is the legal issue surrounding accuracy. On August 20, 2026, the U.S. District Court for the Northern District of California accepted a class-action lawsuit against Oura. Consumers alleged they were misled about the accuracy of the sleep tracking feature. They claimed that the accuracy of sleep stage determination was only 53.18%, little better than a coin toss.

The point at issue in the complaint lies in the measurement principle. Sleep is a phenomenon that occurs in the brain, not in the finger. The medical standard is polysomnography, which involves attaching electrodes to the scalp and face. Ring-type devices work by inferring stages from heart rate and body movement at the fingertip, which is essentially an AI-based estimation.

Oura countered that its products are clearly labeled as not being medical devices. As a legal defense, this is a potentially valid argument. However, questions were raised about how much of the elaborate hypnograms and recovery scores are actual measurements and how much is algorithmically generated. The blow was significant in that it bred distrust toward the core of its marketing.

In terms of patents, Oura has also built a high wall. It is said to hold more than 100 patents worldwide. U.S. Patent No. 11,868,178 broadly covers the basic design of the shape and sensor configuration. In January 2026, it filed infringement suits with the U.S. International Trade Commission against peers including Samsung, Reebok, Huami, and Nexxbase. The barriers to entry for latecomers are rising even higher.

Prospects and Remaining Challenges for the

FDA Clearance Route

Happy Ring’s approach is directly linked to home healthcare. It obtained two FDA 510(k) clearances in succession in September 2024 and June 2025. It is positioned as the first ring-type device to support multi-night at-home sleep testing. It claims to detect sleep apnea and insomnia with 98% accuracy, rivaling hospital-based testing.

One path is the story of AI subscription payments, the other is the story of home healthcare. Both have strong appeal to capital markets. If a ring can handle at-home diagnosis with clinical-grade accuracy, it will become more than a health toy and become a medical tool. That is because it creates clear value in saving time and cost.

However, the meaning of the clearance needs to be understood accurately. FDA 510(k) is a procedure to demonstrate substantial equivalence, not an independent validation of efficacy. It is a framework to show that safety and effectiveness are essentially equivalent to a legally marketed predicate device already on the market. Diagnosis of sleep apnea involves multidimensional signals such as respiratory airflow, blood oxygen, and brain waves. Whether fingertip-only acquisition can replace overnight testing remains a matter of debate in the industry.

Price uncertainty also remains. Happy Ring has not yet disclosed its retail price. Judging by comparable medical-grade wearable devices, it could be significantly higher than consumer products. How the cost will be covered and the system design for reimbursement also remain challenges.

Why Major Players Continue to Wait and See

and the Confusion

Moves by Huawei, Vivo, Honor, Xiaomi, and Apple are ambiguous, neither clearly following nor clearly holding back. There have been reports of prototypes, ecosystem-based entries, and ongoing development, but none has led to a full-scale rollout. Apple’s stance, as a bellwether for consumer electronics, is emblematic. In July 2026 it obtained a patent for a ring-type device, but the focus was not on health measurement.

Apple positions it as an operational interface connecting the iPhone, iPad, Mac, and Vision Pro. The idea is a ring as a gateway into the ecosystem. Even so, no clear product timeline has been presented. There is also a view within the company that it is concerned about cannibalizing Apple Watch sales.

Market size forecasts themselves are unsettled. Fortune Business Insights puts the global market at $417 million in 2025. Omdia’s tally shows shipments exceeding 4 million units in 2025. Global Market Insights forecasts the 2026 market at $1.01 billion, while ElectroIQ’s figure for 2026 reaches $7.46 billion. The gap of several times to tenfold indicates inconsistent definitions, boundaries, and aggregation criteria. This is typical of an early-stage market.

The product has yet to prove useful to the majority of consumers. Being able to measure something and being worth paying to keep using are two different things. The observation that capital is running ahead while the product has not yet made the grade hits the mark. It is understandable that the AI ring is judged to remain at the proof-of-concept stage.

Editorial Opinion

Looking at the short-term impact, we expect the focus over the next 3-6 months to be on Oura’s listing process and the progress of the class-action lawsuit. The dispute over accuracy could spill over into subscription cancellation trends. We assess that each company will be forced to choose between a medical or entertainment-oriented path. Patent disputes are also seen as likely to affect the timing of new product launches.

From a long-term perspective of 1-3 years, we assess that the framework for at-home sleep diagnosis will be key. Whether fingertip-only measurement will be integrated into clinical workflows appears to be the inflection point. We view that consumer products will see limited adoption unless a clear differentiation from wristwatch-type devices is established. We assess that only products meeting the three conditions of price, accuracy, and wearability will survive.

We note questions from the editorial team. To what extent should estimated sleep stage values be presented as medical advice? Who should set the standards for disclosing algorithmic supplementation? We also see open questions as to whether the role of the ring form factor should be measurement or operation.

References

• ” 千亿估值VS“鸡肋”体验，AI戒指是伪需求吗？ ”, by 观网财经© — 虎嗅网, 2026-09-04T12:41:34.000Z (ARR)
• Source URL: https://www.huxiu.com/article/4888687.html?f=rss